Catalyst Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Catalyst Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-11,429	Closed	-$892K	–	584
2015 Q2	$892K	Buy	+11,429	New	+$959K	0.1%	168
2014 Q1	–	Sell	-9,749	Closed	-$1.79M	–	334
2013 Q4	$1.79M	Buy	9,749 +9,372	+2,486%	+$1.72M	0.58%	66
2013 Q3	$83K	Sell	377 -2,052	-84%	-$437K	0.05%	252
2013 Q2	$424K	Buy	+2,429	New	+$633K	0.33%	128

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Capital Advisors's MDGL Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2015, closing a stake of 11,429 shares — an estimated $892K sold.

Catalyst Capital Advisors first reported a position in MDGL in Q2 2013 and held it in 4 quarters. The position peaked at $1.79M in Q4 2013. 84 funds tracked by Wall St. Rank hold MDGL as of Q3 2015.

Catalyst Capital Advisors reported no remaining Madrigal Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Catalyst Capital Advisors sold 11,429 Madrigal Pharmaceuticals shares in Q3 2015, an estimated $892K.
Catalyst Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Catalyst Capital Advisors's Madrigal Pharmaceuticals position peaked at $1.79M in Q4 2013.
84 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.